Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/516
Subject | Predicate | Object | Context |
---|---|---|---|
dailymed-drugs:516 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
dailymed-drugs:516 | rdf:type | dailymed-instance:drugs | lld:dailymed |
dailymed-drugs:516 | rdfs:label | Lisinopril (Tablet) | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:dosage | Hypertension: Initial Therapy: In patients with uncomplicated essential hypertension not on diuretic therapy, the recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20 to 40 mg per day administered in a single daily dose. The antihypertensive effect may diminish toward the end of the dosing interval regardless of the administered dose, but most commonly with a dose of 10 mg daily. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in dose should be considered. Doses up to 80 mg have been used but do not appear to give a greater effect. If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added. Hydrochlorothiazide 12.5 mg has been shown to provide an additive effect. After the addition of a diuretic, it may be possible to reduce the dose of lisinopril. Diuretic Treated Patients: In hypertensive patients who are currently being treated with a diuretic, symptomatic hypotension may occur occasionally following the initial dose of lisinopril. The diuretic should be discontinued, if possible, for two to three days before beginning therapy with lisinopril to reduce the likelihood of hypotension. (See WARNINGS.) The dosage of lisinopril should be adjusted according to blood pressure response. If the patient's blood pressure is not controlled with lisinopril alone, diuretic therapy may be resumed as described above. If the diuretic cannot be discontinued, an initial dose of 5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.) Concomitant administration of lisinopril with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS). Dosage Adjustment in Renal Impairment: The usual dose of lisinopril (10 mg) is recommended for patients with a creatinine clearance>30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance���10 mL/min���30 mL/min (serum creatinine���3 mg/dL), the first dose is 5 mg once daily. For patients with creatinine clearance<10 mL/min (usually on hemodialysis) the recommended initial dose is 2.5 mg. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. See WARNINGS, Anaphylactoid reactions during membrane exposure Dosage or dosing interval should be adjusted depending on the blood pressure response.<br/>Heart Failure: Lisinopril is indicated as adjunctive therapy with diuretics and (usually) digitalis. The recommended starting dose is 5 mg once a day. When initiating treatment with lisinopril in patients with heart failure, the initial dose should be administered under medical observation, especially in those patients with low blood pressure (systolic blood pressure below 100 mmHg). The mean peak blood pressure lowering occurs six to eight hours after dosing. Observation should continue until blood pressure is stable. The concomitant diuretic dose should be reduced, if possible, to help minimize hypovolemia which may contribute to hypotension. (See WARNINGS and PRECAUTIONS, DrugInteractions.) The appearance of hypotension after the initial dose of lisinopril does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. The usual effective dosage range is 5 to 40 mg per day administered as a single daily dose. The dose of lisinopril can be increased by increments of no greater than 10 mg, at intervals of no less than 2 weeks to the highest tolerated dose, up to a maximum of 40 mg daily. Dose adjustment should be based on the clinical response of individual patients. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia: In patients with heart failure who have hyponatremia (serum sodium<130 mEq/L) or moderate to severe renal impairment (creatinine clearance���30 mL/min or serum creatinine>3 mg/dL), therapy with lisinopril should be initiated at a dose of 2.5 mg once a day under close medical supervision. (See WARNINGS and PRECAUTIONS, Drug Interactions.)<br/>Acute Myocardial Infarction: In hemodynamically stable patients within 24 hours of the onset of symptoms of acute myocardial infarction, the first dose of lisinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg of lisinopril once daily. Dosing should continue for six weeks. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers. Patients with a low systolic blood pressure (���120 mmHg) when treatment is started or during the first 3 days after the infarct should be given a lower 2.5 mg oral dose of lisinopril (see WARNINGS). If hypotension occurs (systolic blood pressure���100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure<90 mmHg for more than 1 hour) lisinopril should be withdrawn. For patients who develop symptoms of heart failure, see DOSAGE AND ADMINISTRATION, Heart Failure. Dosage Adjustment in Patients with Myocardial Infarction with Renal Impairment: In acute myocardial infarction, treatment with lisinopril should be initiated with caution in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 2 mg/dL. No evaluation of dosage adjustment in myocardial infarction patients with severe renal impairment has been performed.<br/>Use in Elderly: In general, the clinical response was similar in younger and older patients given similar doses of lisinopril. Pharmacokinetic studies, however, indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients, so that dosage adjustments should be made with particular caution.<br/>Pediatric Hypertensive Patients���6 years of age: The usual recommended starting dose is 0.07 mg/kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients. (See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism and Pharmacodynamics and Clinical Effects.) Lisinopril is not recommend in pediatric patients<6 years or in pediatric patients with glomerular filtration rate<30 mL/min/1.73 min(see CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism and Pharmacodynamics and Clinical Effects and PRECAUTIONS). Preparation of Suspension (for 200 mL of a 1 mg/mL suspension): Add 10 mL of Purified Water USP to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of lisinopril and shake for at least one minute. Add 30 mL of Bicitradiluent and 160 mL of Ora-Sweet SFto the concentrate in the PET bottle and gently shake for several seconds to disperse the ingredients. The suspension should be stored at or below 25��C (77��F) and can be stored for up to four weeks. Shake the suspension before each use. Registered trademark of Alza Corporation Trademark of Paddock Laboratories, Inc. | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:descripti... | Lisinopril is an oral long-acting angiotensin converting enzyme inhibitor. (Lisinopril), a synthetic peptide derivative, is an oral long-acting angiotensin converting enzyme inhibitor. Lisinopril is chemically described as ( S)-1-[N-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its molecular formula is CHNO���2HO and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. It is soluble in water and sparingly soluble in methanol and practically insoluble in ethanol. Lisinopril is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration. Inactive ingredients 2.5, 5, 10, 20, 30 mg tablets���dibasic calcium phosphate (anhydrous), ferric oxide (red), magnesium stearate, mannitol, pregelatinized starch, starch. 40 mg tablets���dibasic calcium phosphate (anhydrous), ferric oxide (yellow), magnesium stearate, mannitol, pregelatinized starch, starch. | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:clinicalP... | Mechanism of Action: Lisinopril inhibits angiotensin converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with lisinopril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1 mEq/L; however, approximately 15% of patients had increases greater than 0.5 mEq/L and approximately 6% had a decrease greater than 0.5 mEq/L. In the same study, patients treated with lisinopril and hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1 mEq/L; approximately 4% of patients had increases greater than 0.5 mEq/L and approximately 12% had a decrease greater than 0.5 mEq/L. (See PRECAUTIONS.) Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated. While the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low-renin hypertension. Although lisinopril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to monotherapy than non-Black patients. Concomitant administration of lisinopril and hydrochlorothiazide further reduced blood pressure in Black and non-Black patients and any racial differences in blood pressure response were no longer evident.<br/>Pharmacokinetics and Metabolism: Adult Patients: Following oral administration of lisinopril, peak serum concentrations of lisinopril occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Declining serum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not appear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25%, with large intersubject variability (6% to 60%) at all doses tested (5 to 80 mg). Lisinopril absorption is not influenced by the presence of food in the gastrointestinal tract. The absolute bioavailability of lisinopril is reduced to about 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects. The oral bioavailability of lisinopril in patients with acute myocardial infarction is similar to that in healthy volunteers. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 hours. Impaired renal function decreases elimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 mL/min. Above this glomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to attain steady state is prolonged. Older patients, on average, have (approximately doubled) higher blood levels and area under the plasma concentration time curve (AUC) than younger patients. (See DOSAGE AND ADMINISTRATION.) Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Multiple doses of lisinopril in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration ofC lisinopril. By whole body autoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses. Pediatric Patients: The pharmacokinetics of lisinopril were studied in 29 pediatric hypertensive patients between 6 years and 16 years with glomerular filtration rate>30 mL/min/1.73 m. After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults. The typical value of lisinopril oral clearance (systemic clearance/absolute bioavailability) in a child weighing 30 kg is 10 L/h, which increases in proportion to renal function.<br/>Pharmacodynamics and Clinical Effects:<br/>Hypertension:: Adult Patients: Administration of lisinopril to patients with hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients. (See WARNINGS.) When given together with thiazide-type diuretics, the blood pressure lowering effects of the two drugs are approximately additive. In most patients studied, onset of antihypertensive activity was seen at one hour after oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by 6 hours. Although an antihypertensive effect was observed 24 hours after dosing with recommended single daily doses, the effect was more consistent and the mean effect was considerably larger in some studies with doses of 20 mg or more than with lower doses. However, at all doses studied, the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was six hours after dosing. In some patients achievement of optimal blood pressure reduction may require two to four weeks of therapy. The antihypertensive effects of lisinopril are maintained during long-term therapy. Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure or a significant increase in blood pressure compared to pretreatment levels. Two dose-response studies utilizing a once daily regimen were conducted in 438 mild to moderate hypertensive patients not on a diuretic. Blood pressure was measured 24 hours after dosing. An antihypertensive effect of lisinopril was seen with 5 mg in some patients. However, in both studies blood pressure reduction occurred sooner and was greater in patients treated with 10, 20 or 80 mg of lisinopril. In controlled clinical studies, lisinopril 20 to 80 mg has been compared in patients with mild to moderate hypertension to hydrochlorothiazide 12.5 to 50 mg and with atenolol 50 to 200 mg; and in patients with moderate to severe hypertension to metoprolol 100 to 200 mg. It was superior to hydrochlorothiazide in effects on systolic and diastolic blood pressure in a population that was��Caucasian. Lisinopril was approximately equivalent to atenolol and metoprolol in effects on diastolic blood pressure and had somewhat greater effects on systolic blood pressure. Lisinopril had similar effectiveness and adverse effects in younger and older (>65 years) patients. It was less effective in Blacks than in Caucasians. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not large. In patients with renovascular hypertension lisinopril has been shown to be well tolerated and effective in controlling blood pressure (see PRECAUTIONS). Pediatric Patients: In a clinical study involving 115 hypertensive pediatric patients 6 to 16 years of age, patients who weighed<50 kg received either 0.625, 2.5 or 20 mg of lisinopril daily and patients who weighed���50 kg received either 1.25, 5, or 40 mg of lisinopril daily. At the end of 2 weeks, lisinopril administered once daily lowered trough blood pressure in a dose-dependent manner with consistent antihypertensive efficacy demonstrated at doses>1.25 mg (0.02 mg/kg). This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mmHg more in patients randomized to placebo than it did in patients who were randomized to remain on the middle and high doses of lisinopril. The dose-dependent antihypertensive effect of lisinopril was consistent across several demographic subgroups: age, Tanner stage, gender, and race. In this study, lisinopril was generally well-tolerated. In the above pediatric studies, lisinopril was given either as tablets or in a suspension for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form (see DOSAGE AND ADMINISTRATION, Preparation of Suspension).<br/>Heart Failure:: During baseline-controlled clinical trials, in patients receiving digitalis and diuretics, single doses of lisinopril resulted in decreases in pulmonary capillary wedge pressure, systemic vascular resistance and blood pressure accompanied by an increase in cardiac output and no change in heart rate. In two placebo-controlled, 12-week clinical studies using doses of lisinopril up to 20 mg, lisinopril as adjunctive therapy to digitalis and diuretics improved the following signs and symptoms due to congestive heart failure: edema, rales, paroxysmal nocturnal dyspnea and jugular venous distention. In one of the studies beneficial response was also noted for: orthopnea, presence of third heart sound and the number of patients classified as NYHA Class III and IV. Exercise tolerance was also improved in this study. The effect of lisinopril on mortality in patients with heart failure has not been evaluated. The once daily dosing for the treatment of congestive heart failure was the only dosage regimen used during clinical trial development and was determined by the measurement of hemodynamic responses.<br/>Acute Myocardial Infarction:: The Gruppo Italiano per lo Studio della Sopravvienza nell'Infarto Miocardico (GISSI - 3) study was a multicenter, controlled, randomized, unblinded clinical trial conducted in 19,394 patients with acute myocardial infarction admitted to a coronary care unit. It was designed to examine the effects of short-term (6 week) treatment with lisinopril, nitrates, their combination, or no therapy on short-term (6 week) mortality and on long-term death and markedly impaired cardiac function. Patients presenting within 24 hours of the onset of symptoms who were hemodynamically stable were randomized, in a 2 x 2 factorial design, to six weeks of either.1) lisinoprilalone (n = 4841), 2) nitrates alone (n = 4869), 3) Lisinopril plus nitrates (n = 4841), or 4)open control (n = 4843). All patients received routine therapies, including thrombolytics (72%), aspirin (84%), and a beta-blocker (31%), as appropriate, normally utilized in acute myocardial infarction (MI) patients. The protocol excluded patients with hypotension (systolic blood pressure���100 mmHg), severe heart failure, cardiogenic shock and renal dysfunction (serum creatinine>2 mg/dL and/or proteinuria>500 mg/24 h). Doses of lisinopril were adjusted as necessary according to protocol. (See DOSAGE AND ADMINISTRATION.) Study treatment was withdrawn at 6 weeks except where clinical conditions indicated continuation of treatment. The primary outcomes of the trial were the overall mortality at 6 weeks and a combined endpoint at six months after the myocardial infarction, consisting of the number of patients who died, had late (day 4) clinical congestive heart failure, or had extensive left ventricular damage defined as ejection fraction���35%, or an akinetic-dyskinetic [A-D] score���45%. Patients receiving lisinopril (n = 9646) alone or with nitrates, had an 11% lower risk of death (2p [two-tailed] = 0.04) compared to patients receiving no lisinopril (n = 9672) (6.4% versus 7.2%, respectively) at six weeks. Although patients randomized to receive lisinopril for up to six weeks also fared numerically better on the combined end-point at 6 months, the open nature of the assessment of heart failure, substantial loss to follow-up echocardiography, and substantial excess use of lisinopril between 6 weeks and 6 months in the group randomized to 6 weeks of lisinopril, preclude any conclusion about this endpoint. Patients with acute myocardial infarction, treated with lisinopril had a higher (9% versus 3.7 %) incidence of persistent hypotension (systolic blood pressure<90 mmHg for more than 1 hour) and renal dysfunction (2.4% versus 1.1%) in-hospital and at six weeks (increasing creatinine concentration to over 3 mg/dL or a doubling or more of the baseline serum creatinine concentration). (See ADVERSE REACTIONS, ACUTE MYOCARDIAL INFARCTION.) | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:activeIng... | dailymed-ingredient:lisinop... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:supply | Lisinopril Tablets, 2.5 mg, light pink, round, flat faced, beveled edge tablets debossed with���RX5���on one side and plain on the other side. They are supplied as follows: NDC63304-531-01 Bottles of 100 NDC63304-531-77 Blister unit-dose of 100 Lisinopril Tablets, 5 mg, light pink, round, flat faced, beveled edge, bisected tablets debossed with���RX���above the bisect and���532���below the bisect, and plain on the other side. They are supplied as follows: NDC 63304-532-01 Bottles of 100 NDC 63304-532-10 Bottles of 1000 NDC 63304-532-77 Blister unit-dose of 100 Lisinopril Tablets, 10 mg, light pink, round, flat faced, beveled edge tablets debossed with���RX 533���on one side and plain on the other side. They are supplied as follows: NDC 63304-533-01 Bottles of 100 NDC 63304-533-10 Bottles of 1000 NDC 63304-533-77 Blister unit-dose of 100 Lisinopril Tablets, 20 mg, light rust, round, flat faced, beveled edge tablets debossed with���RX 534���on one side and plain on the other side. They are supplied as follows: NDC 63304-534-01 Bottles of 100 NDC 63304-534-10 Bottles of 1000 NDC 63304-534-77 Blister unit-dose of 100 Lisinopril Tablets, 30 mg, rust, round, flat faced, beveled edge tablets debossed with���RX 599���on one side and plain on the other side. They are supplied as follows: NDC 63304-599-01 Bottles of 100 NDC 63304-599-10 Bottles of 1000 Lisinopril Tablets, 40 mg, light yellow, round, flat faced, beveled edge tablets debossed with���RX 535���on one side and plain on the other side. They are supplied as follows: NDC 63304-535-01 Bottles of 100 NDC 63304-535-10 Bottles of 1000 NDC 63304-535-77 Blister unit-dose of 100 Store at 20���25��C (68���77��F). (See USP Controlled Room Temperature). Protect from moisture, freezing and excessive heat. Dispense in a tight container. *AN69 is a registered trademark of Hospal Ltd. Manufactured for: Ranbaxy Pharmaceuticals Inc. Jacksonville, FL 32257 USA By: Ohm Laboratories Inc. North Brunswick, NJ 08902 USA June 2007 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:boxedWarn... | USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, Lisinopril should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality. | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:activeMoi... | dailymed-ingredient:lisinop... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:mannito... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:magnesi... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:starch | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:pregela... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:dibasic... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:inactiveI... | dailymed-ingredient:ferric_... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:319 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:561 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:1283 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:74 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:89 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:797 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:949 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:1021 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:1408 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:1455 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:2174 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:2701 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:3283 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:3639 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:3728 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:3730 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:possibleD... | diseasome-diseases:3831 | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:overdosag... | Following a single oral dose of 20 g/kg, no lethality occurred in rats and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Lisinopril can be removed by hemodialysis. (See WARNINGS, Anaphylactoid Reactions During Membrane Exposure.) | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:genericMe... | Lisinopril | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:fullName | Lisinopril (Tablet) | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:adverseRe... | Lisinopril has been found to be generally well tolerated in controlled clinical trials involving 1969 patients with hypertension or heart failure. For the most part, adverse experiences were mild and transient.<br/>HYPERTENSION: In clinical trials in patients with hypertension treated with lisinopril, discontinuation of therapy due to clinical adverse experiences occurred in 5.7% of patients. The overall frequency of adverse experiences could not be related to total daily dosage within the recommended therapeutic dosage range. For adverse experiences occurring in greater than 1% percent of patients with hypertension treated with lisinopril or lisinopril plus hydrochlorothiazide in controlled clinical trials and more frequently with lisinopril and/or lisinopril plus hydrochlorothiazide than placebo, comparative incidence data are listed in the table below: Chest pain and back pain were also seen but were more common on placebo than lisinopril.<br/>HEART FAILURE: In controlled studies in patients with heart failure treated with lisinopril for up to four years, discontinuation of therapy due to clinical adverse experiences occurred in 11% of patients. In controlled studies in patients with heart failure, therapy was discontinued in 8.1% of patients treated with lisinopril for up to 12 weeks, compared to 7.7% of patients treated with placebo for 12 weeks. The following table lists those adverse experiences which occurred in greater than 1% of patients with heart failure treated with lisinopril or placebo for up to 12 weeks in controlled clinical trials and more frequently on lisinopril than placebo. Also observed at>1% with lisinopril but more frequent or as frequent on placebo than lisinopril in controlled trials were asthenia, angina pectoris, nausea, dyspnea, cough, and pruritus. Worsening of heart failure, anorexia, increased salivation, muscle cramps, back pain, myalgia, depression, chest sound abnormalities and pulmonary edema were also seen in controlled clinical trials, but were more common on placebo than lisinopril. In the two-dose ATLAS trial in heart failure patients, withdrawals due to adverse events were not different between the low and high groups, either in total number of discontinuation (17 to 18%) or in rare specific events (<1%). The following adverse events, mostly related to ACE inhibition, were reported more commonly in the high dose group: NPN= non-protein nitrogen<br/>Acute Myocardial Infarction: In the GISSI - 3 trial, in patients treated with lisinopril for six weeks following acute myocardial infarction, discontinuation of therapy occurred in 17.6% of patients. Patients treated with lisinopril had a significantly higher incidence of hypotension and renal dysfunction compared with patients not taking lisinopril. In the GISSI - 3 trial, hypotension (9.7%), renal dysfunction (2%), cough (0.5%), post-infarction angina (0.3%), skin rash and generalized edema (0.01%), and angioedema (0.01%) resulted in withdrawal of treatment. In elderly patients treated with lisinopril, discontinuation due to renal dysfunction was 4.2%. Other clinical adverse experiences occurring in 0.3 to 1% of patients with hypertension or heart failure treated with lisinopril in controlled trials and rarer, serious, possibly drug-related events reported in uncontrolled studies or marketing experience are listed below, and within each category, are in order of decreasing severity: Body as a Whole: Anaphylactoid reactions (see WARNINGS, Anaphylactoid and Possibly Related Reactions), syncope, orthostatic effects, chest discomfort, pain, pelvic pain, flank pain, edema, facial edema, virus infection, fever, chills, malaise. Cardiovascular: Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high-risk patients (see WARNINGS, Hypotension); pulmonary embolism and infarction, arrhythmias (including ventricular tachycardia, atrial tachycardia, atrial fibrillation, bradycardia and premature ventricular contractions), palpitations, transient ischemic attacks, paroxysmal nocturnal dyspnea, orthostatic hypotension, decreased blood pressure, peripheral edema, vasculitis. Digestive: Pancreatitis, hepatitis (hepatocellular or cholestatic jaundice) (see WARNINGS, Hepatic Failure), vomiting, gastritis, dyspepsia, heartburn, gastrointestinal cramps, constipation, flatulence, dry mouth. Hematologic: Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia, and thrombocytopenia. Endocrine: Diabetes mellitus. Metabolic: Weight loss, dehydration, fluid overload, gout, weight gain. Cases of hypoglycemia in diabetic patients on oral antidiabetic agents or insulin have been reported in postmarketing experience (See PRECAUTIONS, Drug Interactions). Musculoskeletal: Arthritis, arthralgia, neck pain, hip pain, low back pain, joint pain, leg pain, knee pain, shoulder pain, arm pain, lumbago. Nervous System/Psychiatric: Stroke, ataxia, memory impairment, tremor, peripheral neuropathy (e.g., dysesthesia), spasm, paresthesia, confusion, insomnia, somnolence, hypersomnia, irritability, and nervousness. Respiratory System: Malignant lung neoplasms, hemoptysis, pulmonary infiltrates, eosinophilic pneumonitis, bronchospasm, asthma, pleural effusion, pneumonia, bronchitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis, pharyngeal pain, pharyngitis, rhinitis, rhinorrhea. Skin: Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema, flushing, diaphoresis. Other severe skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome) have been reported rarely; causal relationship has not been established. Special Senses: Visual loss, diplopia, blurred vision, tinnitus, photophobia, taste disturbances. Urogenital System: Acute renal failure, oliguria, anuria, uremia, progressive azotemia, renal dysfunction (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), pyelonephritis, dysuria, urinary tract infection, breast pain. Miscellaneous: A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia and leukocytosis. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms. Angioedema: Angioedema has been reported in patients receiving lisinopril (0.1%) with an incidence higher in Black than in non-Black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with lisinopril should be discontinued and appropriate therapy instituted immediately.(See WARNINGS.) In rare cases, intestinal angioedema has been reported in postmarketing experience. Hypotension: In hypertensive patients, hypotension occurred in 1.2% and syncope occurred in 0.1% of patients with an incidence higher in Black than in non-Black patients. Hypotension or syncope was a cause for discontinuation of therapy in 0.5 % of hypertensive patients. In patients with heart failure, hypotension occurred in 5.3% and syncope occurred in 1.8% of patients. These adverse experiences were possibly dose related (see above data from ATLAS trial) and cause discontinuation of therapy in 1.8% of these patients. In patients treated with lisinopril for six weeks after acute myocardial infarction, hypotension (systolic blood pressure���100 mmHg) resulted in discontinuation of therapy in 9.7% of the patients. (See WARNINGS.) Fetal/Neonatal Morbidity and Mortality: See WARNINGS, Fetal/Neonatal Morbidity and Mortality. Cough: See PRECAUTIONS, Cough. Pediatric Patients: No relevant differences between the adverse experience profile for pediatric patients and that previously reported for adult patients were identified.<br/>Clinical Laboratory Test Findings: Serum Electrolytes: Hyperkalemia (see PRECAUTIONS), hyponatremia. Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 2% of patients with essential hypertension treated with lisinopril alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis. (See PRECAUTIONS.) Reversible minor increases in blood urea nitrogen and serum creatinine were observed in approximately 11.6% of patients with heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage ofthe diuretic was decreased. Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g% and 1.3 vol%, respectively) occurred frequently in patients treated with lisinopril but were rarely of clinical importance in patients without some other cause of anemia. In clinical trials, less than 0.1% of patients discontinued therapy due to anemia. Hemolytic anemia has been reported; a causal relationship to lisinopril cannot be excluded. Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred (see WARNINGS, Hepatic Failure). In hypertensive patients, 2% discontinued therapy due to laboratory adverse experiences, principally elevations in blood urea nitrogen (0.6%), serum creatinine (0.5%) and serum potassium (0.4%). In the heart failure trials, 3.4% of patients discontinued therapy due to laboratory adverse experiences, 1.8% due to elevations in blood urea nitrogen and/or creatinine and 0.6% due to elevations in serum potassium. In the myocardial infarction trial, 2% of patients receiving lisinopril discontinued therapy due to renal dysfunction (increasing creatinine concentration to over 3 mg/dL or a doubling or more of the baseline serum creatinine concentration); less than 1% of patients discontinued therapy due to other laboratory adverse experiences: 0.1% with hyperkalemia and less than 0.1% with hepatic enzyme alterations. | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:indicatio... | Hypertension: Lisinopril is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.<br/>Heart Failure: Lisinopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.<br/>Acute Myocardial Infarction: Lisinopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers. In using lisinopril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS.) In considering the use of lisinopril, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Anaphylactoid and Possibly Related Reactions, Head and Neck Angioedema). | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
dailymed-drugs:516 | dailymed-instance:name | Lisinopril | lld:dailymed |
http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:516 | lld:dailymed |
diseasome-diseases:319 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:561 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:1283 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:74 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:89 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:797 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:949 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:1021 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:1408 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:1455 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:2174 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:2701 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:3283 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:3639 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:3728 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:3730 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |
diseasome-diseases:3831 | diseasome-instance:possible... | dailymed-drugs:516 | lld:diseasome |